Esomeprazole + Esomeprazole

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Non Erosive Reflux Disease

Conditions

Non Erosive Reflux Disease, Chronic Gastritis

Trial Timeline

Apr 1, 2010 → Jun 1, 2011

NCT ID

NCT01119768

About Esomeprazole + Esomeprazole

Esomeprazole + Esomeprazole is a approved stage product being developed by AstraZeneca for Non Erosive Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01119768. Target conditions include Non Erosive Reflux Disease, Chronic Gastritis.

What happened to similar drugs?

5 of 12 similar drugs in Non Erosive Reflux Disease were approved

Approved (5) Terminated (0) Active (7)

✅Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenoneEisaiApproved

✅Esomeprazole + LansoprazoleAstraZenecaApproved

✅esomeprazole magnesium (oral medication)AstraZenecaApproved

✅Omeprazole/sodium bicarbonateBausch HealthApproved

🔄E3810 + E3810 + PlaceboEisaiPhase 3

🔄RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUMEisaiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01119768	Approved	Completed	Apr 1, 2010	Jun 1, 2011	Non Erosive Reflux Disease
NCT00361985	Approved	Withdrawn	Jan 1, 2008	Jul 1, 2011	Anastomotic Stricture
NCT00629564	Approved	Completed	Sep 1, 2002	Oct 1, 2002	GERD
NCT00625495	Approved	Completed	Sep 1, 2002	Nov 1, 2002	Gastroesophageal Reflux Disease
NCT00635414	Approved	Completed	Aug 1, 2002	Oct 1, 2002	GERD

Competing Products

20 competing products in Non Erosive Reflux Disease

See all competitors

Product	Company	Stage	Hype Score
YH1885L(Revaprazan) + Esomeprazole 20mg + placebo	Yuhan	Phase 2	35
E3810 + E3810 + Placebo	Eisai	Phase 3	40
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM	Eisai	Phase 3	40
Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone	Eisai	Approved	43
ABT-981 + Placebo for ABT-981	AbbVie	Phase 2	35
Omeprazole	AstraZeneca	Phase 3	40
Esomeprazole + Lansoprazole	AstraZeneca	Approved	43
Nexium 20mg + Nexium 10mg	AstraZeneca	Phase 3	47
Omeprazole	AstraZeneca	Phase 3	40
AZD0865	AstraZeneca	Phase 2	35
Esomeprazole + Lansoprazole	AstraZeneca	Approved	43
AZD0865	AstraZeneca	Phase 2	35
esomeprazole magnesium (oral medication)	AstraZeneca	Approved	43
Alendronate Effervescent Oral Tablet	Amgen	Phase 2	35
Omeprazole/sodium bicarbonate	Bausch Health	Approved	37
Vonoprazan	Phathom Pharmaceuticals	Phase 1	23
Vonoprazan + Lansoprazole	Phathom Pharmaceuticals	Phase 3	34
Vonoprazan + Placebo	Phathom Pharmaceuticals	Phase 2	29
Vonoprazan	Phathom Pharmaceuticals	Pre-clinical	27
Vonoprazan + Placebo	Phathom Pharmaceuticals	Phase 3	34